{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:27:17Z","timestamp":1793910437212,"version":"4.8.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.esmoop.2025.105875","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T01:53:55Z","timestamp":1762394035000},"page":"105875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparing [18F]FDG\u2013positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5165-4168","authenticated-orcid":false,"given":"J.J.","family":"Garc\u00eda-Mosquera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2204-2014","authenticated-orcid":false,"given":"J.M.","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ruiz-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-8869","authenticated-orcid":false,"given":"A.","family":"Stradella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-5994","authenticated-orcid":false,"given":"B.","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7816-7589","authenticated-orcid":false,"given":"S.","family":"Escriv\u00e1-de-Roman\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8314-0241","authenticated-orcid":false,"given":"L.","family":"Calvo Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gebhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7740-4615","authenticated-orcid":false,"given":"K.","family":"Kerrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-3665","authenticated-orcid":false,"given":"G.","family":"Antonarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-4577","authenticated-orcid":false,"given":"S.","family":"Santasusagna Canal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8133-9983","authenticated-orcid":false,"given":"J.","family":"Rodr\u00edguez-Morato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sampayo-Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-8293","authenticated-orcid":false,"given":"A.","family":"Llombart-Cussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.105875_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10549-020-05587-5","article-title":"Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes","volume":"181","author":"Hassett","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2025.105875_bib2","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.esmoop.2025.105875_bib3","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.105875_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105875_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.105875_bib6","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","volume":"403","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.105875_bib7","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","article-title":"Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","volume":"22","author":"P\u00e9rez-Garc\u00eda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105875_bib8","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.3390\/jcm12165355","article-title":"Comparison of MRI vs. [18F]FDG PET\/CT for treatment response evaluation of primary breast cancer after neoadjuvant chemotherapy: literature review and future perspectives","volume":"12","author":"Caracciolo","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.esmoop.2025.105875_bib9","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdv161","article-title":"Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration","volume":"26","author":"Bossuyt","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105875_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(24)00104-9","article-title":"MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II\u2013III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study","volume":"25","author":"van der Voort","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105875_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clbc.2012.01.009","article-title":"Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile","volume":"12","author":"Kuzucan","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.esmoop.2025.105875_bib12","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2967\/jnumed.112.119271","article-title":"18F-FDG PET\/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO","volume":"54","author":"Gebhart","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.esmoop.2025.105875_bib13","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1200\/JCO.2014.60.0353","volume":"33","author":"Lin","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105875_bib14","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170710","article-title":"Patient perspectives on repeated MRI and PET\/CT examinations during neoadjuvant treatment of esophageal cancer","volume":"91","author":"Goense","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.esmoop.2025.105875_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41523-020-00203-7","article-title":"Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL","volume":"6","author":"Li","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2025.105875_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/tomography11030026","article-title":"MRI-based model for personalizing neoadjuvant treatment in breast cancer","volume":"11","author":"Li","year":"2025","journal-title":"Tomography"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:51:31Z","timestamp":1773280291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2059702925017442"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105875","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing [18F]FDG\u2013positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105875"}}